166 completed, 70 active not recruiting, 40 terminated, 27 recruiting. 208 Phase 2, 135 Phase 1, 46 Phase 3, 4 Phase 4, 3 Early Phase 1.
Follow ibrutinib: new trials by email Literature Review of ibrutinib trials Research Report on ibrutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma Rocbrutinib, Ibrutinib, Acalabrutinib - Mantle Cell Lymphoma | Phase 3 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 394 | 2026-02-05 | 2026-02-06 |
| Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy Venetoclax combined with Ibrutinib, Venetoclax combined with Zanubrutinib, Venetoclax combined with Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 79 | 2025-12-01 | 2025-11-25 |
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | VA Office of Research and Development | 100 | 2025-10-01 | 2025-10-14 |
| Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia Ibrutinib, Bendamustine, Rituximab - Waldenström Macroglobulinemia (WM) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2025-09-01 | 2025-09-11 |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2025-08-13 | 2026-07-14 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 27 | 2025-05-29 | 2026-01-30 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-09-25 |
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies BTK inhibitor (Ibrutinib or Acalabrutinib) - Chronic B-cell Malignancies, BTK Inhibitors | Unknown | University Hospital, Caen | 15000 | 2024-07-25 | 2024-08-21 | |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia Ibrutinib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 333 | 2024-05-30 | 2026-09-25 |
| Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia Individual Physical Activity Intervention (IPAI), Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell | Recruiting | Janssen Cilag S.A.S. | 180 | 2024-05-27 | 2026-09-25 | |
| CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma KTE-X19, Ibrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | Christian Schmidt, MD | 150 | 2024-02-15 | 2024-07-01 |
| Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma Methotrexate, Rituximab (where available), Ibrutinib - Non-hodgkin Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 30 | 2024-02-13 | 2026-09-15 |
Showing 20 of 352. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (123) · Lymphoma, Mantle-Cell (68) · Lymphoma, Large B-Cell, Diffuse (40) · Lymphoma, Non-Hodgkin (32) · Lymphoma, Follicular (30) · Lymphoma (29) · Waldenstrom Macroglobulinemia (29) · Recurrence (26) · Lymphoma, B-Cell (22) · Lymphoma, B-Cell, Marginal Zone (19) · Neoplasms (16) · Bronchiolitis Obliterans Syndrome (15) · Leukemia (14) · Leukemia, B-Cell (10) · Burkitt Lymphoma (9)
Pharmacyclics LLC. (31) · Janssen Research & Development, LLC (30) · National Cancer Institute (NCI) (25) · M.D. Anderson Cancer Center (24) · Memorial Sloan Kettering Cancer Center (11) · Dana-Farber Cancer Institute (10) · Mayo Clinic (8) · Incyte Corporation (6) · German CLL Study Group (5) · Janssen Pharmaceutical K.K. (5) · AbbVie (4) · City of Hope Medical Center (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Jennifer Woyach (4)
United States (232) · Spain (52) · France (51) · Germany (49) · Italy (47) · Belgium (44) · United Kingdom (44) · Poland (35) · Australia (34) · Canada (32) · Israel (30) · Czechia (27) · Sweden (27) · China (26) · Turkey (Türkiye) (24)
Christian Grommes, MD (4) · Kami Maddocks, MD (4) · Brian Jonas (3) · Jennifer Woyach, MD (3) · Michael Choi, MD (3) · Nitin Jain (3) · Rahul Lakhotia, M.D. (3) · Sikander Ailawadhi, M.D. (3) · Andre Goy, MD (2)
PMID 31196847, PMID 26182309, PMID 28751558, PMID 34398557, PMID 34865212, PMID 38620092, PMID 40266025, PMID 25381051, PMID 34608724, PMID 40674744, PMID 23886836, PMID 25724156, PMID 26193343, PMID 26813675, PMID 27503501, PMID 29437592, PMID 29470582, PMID 29880603, PMID 31260802, PMID 32209572, PMID 34086865, PMID 34102349, PMID 34797699, PMID 35014928, PMID 35377947, PMID 36617990, PMID 37315225, PMID 38502198, PMID 39563886, PMID 23045577, PMID 23782157, PMID 23782158, PMID 24332241, PMID 24523121, PMID 24659631, PMID 24699307, PMID 24881631, PMID 25150798, PMID 25355819, PMID 25488930, PMID 25555420, PMID 25755291, PMID 25853747, PMID 26059948, PMID 26116658, PMID 26297574, PMID 26337493, PMID 26430171, PMID 26588924, PMID 26639149
2015 (12), 2014 (9), 2016 (8), 2017 (6), 2023 (6), 2019 (5), U10CA180821 (5), UM1CA186712 (5), 2018 (4), P30CA015083 (3), P30CA016058 (3), P30CA093373 (3), U01CA076576 (3), U10CA180820 (3), K24CA201524 (2)